Amgen Inc (CEUX:AMGd) has shown varied financial performance across different metrics over the past decade. The company's revenue has grown steadily, with a 10-year annual growth rate of 9.20%, a 5-year rate of 9.90%, and a 1-year rate of 9.50%. This consistency indicates a robust business model capable of sustaining growth over time.
Earnings per share (EPS) without non-recurring items (NRI) have also seen positive trends, with a 10-year growth rate of 4.60%. However, this metric has dipped slightly over the past five years at -2.60%, before rebounding with a strong 23.50% increase in the most recent year. EBIT and EBITDA have followed similar patterns, with 10-year growth rates of 4.40% and 6.60%, respectively, and notable 1-year increases of 30.80% and 10.50%.
Free cash flow, a critical indicator of financial health, has grown at a modest 2.50% over the past decade, but has faced challenges recently with a 1-year decline of -4.30%. Despite this, Amgen's dividends have shown resilience, growing at an impressive 11.10% over 10 years and 8.40% over five years, with a 1-year increase of 5.80%. Book value has fluctuated, with a 10-year decrease of -12.90% but a significant 1-year surge of 56.70%.
The company's total return over the past year stands at 43.30%, highlighting strong investor returns. These financial metrics provide a comprehensive view of Amgen's performance, reflecting both areas of strength and those requiring attention.